Aptamer Group plc announces the second phase of its on-going partnership with Neuro-Bio to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease.

AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.

Research partnership aims to build strong pharma and academic collaborations in sharing data and clinical samples to develop biomarker-based diagnostics for Alzheimer’s Disease.

Study confirms ALZmetrixTM whole blood test can detect people at high risk of developing full Alzheimer’s Disease.

Newly-launched module set to accelerate drug discovery in therapeutic areas such as neuropsychiatry, epilepsy and neurodegeneration.

Synthace has released a comprehensive analyst report that sheds light on the industry challenges faced by researchers and highlights opportunities for improvement.

AMSBIO, is proud to announce its collaboration with WARR Space Labs, a student group from the Technical University of Munich (TUM).

Aptamer Group plc and Neuro-Bio announce success in the development of Optimer binders to enable a lateral flow test for the early diagnosis of Alzheimer’s disease.

Scribe Therapeutics Inc. has announced a strategic collaboration with Prevail Therapeutics, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Samsara Therapeutics has announced the company’s autophagy-inducing candidate SAM001, the first agent of its class to enter clinical trials.